Dr. Swiger is a successful researcher and developer in clinical Dx, forensics, and environmental testing. His 28-year career has spanned applications and devices widely utilized in government, commercial Dx, and testing-services markets. Notably, Roy was the Point of Contact (POC) for tech transfer of whole mouse chromosome paints for use in fluorescence in situ hybridization (FISH) while at Lawrence Livermore National Laboratory (LLNL). While at MRIGlobal, he developed the PathAlert™ multiplex pathogen detection product-line licensed to Invitrogen/Thermo- Fisher and co-marketed with Agilent. He served as CSO for Escent Technologies where he led a team developing a handheld NIR-instrument used for particulate and powder analysis to identify illegal drugs, pharmaceuticals, and pathogens. More recently, as the Director of Advanced Technology Programs at IntegenX Inc., Dr. Swiger contributed to the development and commercialization of a portable, autonomous sample-in/answer-out forensic DNA-lab-in-a-box, acquired by Thermo-Fisher Life Technologies. Dr. Swiger has the hard-to-find balance of technical and business skills needed to lead Acenxion Biosystems.
Andrew’s 36-year career is a list of successively more impressive engineering accomplishments two of which uniquely demonstrate his ability to actualize Acenxion’s project. Andrew led the consulting design and manufacturing team for Time Warner’s DVD duplication project requiring a $10MM dust free engineering lab and 18Mohm water with multiple plasma chambers and laser EMF encoding equipment. The tolerances for the project were measured in angstroms. Together with Dr. Swiger, Andrew established a 170025 and ASCLD accredited DNA forensic services lab, and created a custom LIMS with analytical applications and interconnectivity for all instrumentation including the RapidHIT mobile instrument. This project went from concept through prototypes to sales of regulatory compliant units. Law enforcement agencies in 10+ states use these lab services and LIMS including on-site DNA testing and databasing. His demonstrated engineering and manufacturing expertise is a vital asset to Acenxion Biosystems.
Dr. Sachidevi Puttaswamy is considered a world expert in bulk capacitance detection of bacteria in solution and is a named inventor on multiple patents in this scientific area. She has authored or co-authored 25+ publications in her field, presented at multiple highly-regarded conferences, and also sat as an official reviewer of federal grant applications. Perhaps most importantly, Sachi brings a unique balance of interdisciplinary skills between the biological, experimental, and engineering needs of Acenxion's important work.
Howard has a history of remarkable startup success. He was involved in twelve biotech startups of which eleven have enjoyed exits by way of acquisition or IPO. In particular, he has excelled in developing market categories, sales strategies, and performed all senior executive functions. Howard’s skills are especially relevant to Acenxion as he has raised over $200 million in funding for life science firms and excelled at introducing new technology into mature markets. He has personally invested capital in Acenxion Biosystems.
Dr. Carter has been a successful executive decision maker at some of the world’s most recognizable life-science industries as well as personally involved in bringing biotechnology from concept to market launch. As president of BioNexus, he mentored a multitude of startups and executives while developing extensive connections in the startup and VC community. Wayne’s skills with large firms will be vital to Acenxion developing strategic partnerships.
Brian enjoyed 15 years as a product developer in the financial services industry. Every major product he helped design is active and profitable. He’s an engaged angel investor and brings considerable IP, finance, and governance abilities. As a two-time state-level Baldrige quality examiner, Brian is uniquely skilled at integrating business functions within small teams and constrained resources. He has personally invested capital in Acenxion.
Acenxion Biosystems, Inc. All rights reserved. © 2024
Website design and development by Pixel Jam Digital
